Over 20% of all U.S. prescriptions are never filled. For high-cost therapies, this problem intensifies: 60% of prescriptions costing $500 or more out-of-pocket are abandoned, according to Healthcare IT News. This widespread non-adherence drains substantial revenue from life sciences companies and creates a significant barrier to patient care.
Life sciences executives express high optimism for future growth and profitability, with 75% anticipating revenue and margin increases, as reported by Deloitte. However, this outlook appears disconnected from the significant portion of prescribed therapies that never reach patients, undermining both health outcomes and potential revenue.
Companies that strategically invest in AI to improve patient adherence will not only secure their projected revenue growth but also establish a new standard for value in healthcare. Without aggressive AI deployment to combat prescription abandonment, executives' optimism for future growth is dangerously misplaced.
The Business Imperative for Patient Adherence
Life sciences executives project future financial growth, with 57% predicting margin expansions. This optimism drives significant investment in digital transformation, with nearly 60% of executives closely monitoring AI and planning increased generative AI investments across the value chain, according to Deloitte. This focus on AI shows a clear strategic shift: executives recognize that digital transformation, especially in improving patient pathways, is crucial for realizing future profitability.
Improving patient adherence is no longer merely a clinical concern; it is a core business strategy directly impacting revenue and margin expansion. Addressing the gap between prescribed and filled medications offers a direct opportunity to convert unrealized revenue into actual sales, supporting anticipated growth and strengthening the business case for health outcomes in life sciences by 2026.
